Biotech Values

[Solar_Express]

EBS Partnerships Shares of Emergent BioSolutions Inc. (EBS) announced a five-year deal with Johnson & Johnson (JNJ) to manufacture the drug substance for the drugmaker's still-investigational COVID-19 vaccine. J&J will pay $480 million for two years of Emergent's contract development and manufacturing services. The two companies had previously announced in April (http://www.marketwatch.com/story/jj-to-pay-emergent-135-million-as-part-of-covid-19-vaccine-manufacturing-deal-2020-04-24) a deal to reserve manufacturing capacity for J&J's vaccine candidate. Emergent has also announced coronavirus vaccine manufacturing deals with AstraZeneca (AZN.LN), Novavax (NVAX) and Vaxart Inc. (VXRT) as part of a new strategy (http://www.marketwatch.com/story/race-for-a-covid-19-vaccine-has-drug-makers-scaling-up-manufacturing-before-one-is-developed-2020-06-25) to build out manufacturing capacity for COVID-19 vaccines before they have proven their efficacy or safety.

https://ih.advfn.com/stock-market/NYSE/emergent-biosolutions-EBS/stock-price